CN116019801B - Amino acid composition for promoting endogenous growth hormone secretion - Google Patents

Abstract

The present invention provides an amino acid composition for promoting secretion of endogenous growth hormone, the composition comprising: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine alpha-ketoglutarate, alanylglutamine, beta-alanine and pyroglutamate. The composition of the invention can effectively promote the secretion of endogenous growth hormone and promote the level of endogenous growth hormone. In addition, the medicine is convenient to take, has good compliance and is helpful for ensuring long-term efficacy.

Description

Amino acid composition for promoting endogenous growth hormone secretion

Technical Field

The present invention relates to the biological field, and in particular to an amino acid composition for promoting the secretion of endogenous growth hormone.

Background technique

Human Growth Hormone (hGH) is a peptide hormone secreted by the anterior pituitary gland of the human body. It can promote the growth of bones, internal organs and the whole body, promote protein synthesis, affect fat and mineral metabolism, and play a key role in human growth and development. At present, the options that can effectively increase the level of growth hormone in the human body are extremely limited, and they mainly revolve around exogenous supplementation through a variety of recombinant human growth hormone injections. Although this method can effectively and quickly increase the level of growth hormone, it has problems such as extremely high prices, the need for periodic injections that make it difficult for users to comply, and frequent missed injections, which makes it difficult to guarantee long-term efficacy. At present, promoting the secretion of endogenous growth hormone by oral administration to increase the level of growth hormone has always been a frontier hotspot in research and development in this field, but no effective technology has yet emerged.

Summary of the invention

The present invention aims to solve the technical problems existing in the prior art to at least a certain extent. To this end, the present invention proposes a composition and a medicine, a health food, a special medical formula food and a feed containing the composition and an application thereof. The composition of the present invention can effectively promote the secretion of endogenous growth hormone and increase the level of endogenous growth hormone. In addition, the composition is convenient to take and has good compliance, which helps to ensure long-term efficacy.

In one aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, the composition includes: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine α-ketoglutarate, alanyl glutamine, β-alanine and pyroglutamate. Thus, the composition according to an embodiment of the present invention can effectively promote the secretion of endogenous growth hormone and improve the level of endogenous growth hormone.

According to an embodiment of the present invention, the above composition may also have at least one of the following additional technical features:

According to an embodiment of the present invention, the weight ratio of tyrosine to ornithine is (1-2):(1-2); the weight ratio of alanyl-glutamine to arginine is (1-2):(1-2).

According to an embodiment of the present invention, the composition comprises: 8-12 parts by weight of tyrosine; 8-12 parts by weight of arginine; 8-12 parts by weight of ornithine; 5-7 parts by weight of lysine; 5-7 parts by weight of glutamine; 5-7 parts by weight of glycine; 5-7 parts by weight of isoleucine; 5-7 parts by weight of leucine; 5-7 parts by weight of valine; 5-7 parts by weight of threonine; 5-7 parts by weight of methionine; 5-7 parts by weight of phenylalanine; 5-7 parts by weight of ornithine α-ketoglutarate; 8-12 parts by weight of alanyl-glutamine; 5-7 parts by weight of β-alanine; and 5-7 parts by weight of pyroglutamate.

According to an embodiment of the present invention, the composition comprises: 10 parts by weight of tyrosine; 10 parts by weight of arginine; 10 parts by weight of ornithine; 6.7 parts by weight of lysine; 6.7 parts by weight of glutamine; 6.7 parts by weight of glycine; 6.7 parts by weight of isoleucine; 6.7 parts by weight of leucine; 6.7 parts by weight of valine; 6.7 parts by weight of threonine; 6.7 parts by weight of methionine; 6.7 parts by weight of phenylalanine; 6.7 parts by weight of ornithine α-ketoglutarate; 10 parts by weight of alanyl-glutamine; 6.7 parts by weight of β-alanine; 6.7 parts by weight of pyroglutamate.

In another aspect of the present invention, the present invention provides a medicine, health food, special medical formula food or feed. According to an embodiment of the present invention, the medicine, health food, special medical formula food or feed comprises: the above-mentioned composition. Thus, the medicine, health food, special medical formula food or feed according to the embodiment of the present invention can effectively promote the secretion of endogenous growth hormone and increase the level of growth hormone.

According to an embodiment of the present invention, the dosage form of the medicine, health food, special medical purpose formula food or feed is selected from a mixture, tablet, granule, syrup, capsule or oral solution.

In another aspect of the present invention, the present invention provides the use of the above-mentioned composition in the preparation of medicines, health foods, special medical formula foods or feeds. According to an embodiment of the present invention, the medicines, health foods, special medical formula foods or feeds are used to promote the secretion of endogenous growth hormone.

According to an embodiment of the present invention, the medicine is used for preventing or treating diseases caused by endogenous growth hormone deficiency.

According to an embodiment of the present invention, the disease is selected from dwarfism and/or osteoporosis.

According to an embodiment of the present invention, the administration method of the medicine, health food, special medical purpose formula food or feed is selected from oral administration.

Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and/or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

Figure 1 shows the analysis of whole blood growth hormone levels in mice after the control group and the experimental group 1 were fed with formula;

Figure 2 shows the analysis of whole blood growth hormone levels in mice after the control group and the experimental group 2-4 were fed with formula;

FIG3 shows the analysis of whole blood growth hormone levels in mice after the mice in the control group and the experimental group were fed with formula 5-7.

Detailed ways

The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

The present invention provides a composition and its use, a medicine, a health food, a special medical purpose formula food and a feed, which will be described in detail below.

combination

In one aspect of the present invention, the present invention provides a composition. According to an embodiment of the present invention, the composition comprises: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine alpha-ketoglutarate, alanylglutamine, beta-alanine and pyroglutamate.

The inventors of the present invention have found through a large number of experimental optimization and analysis that compounding tyrosine (L-Tyrosine), arginine (L-Arginine), ornithine (L-Ornithine), lysine (L-Lysine), glutamine (L-Glutamine), glycine (L-Glycine), isoleucine (L-Isoleucine), leucine (L-Leucine), valine (L-Valine), threonine (L-Threonine), methionine (L-Methionine), phenylalanine (L-Phenylalanine), ornithine alpha-ketoglutarate (Ornithine Alpha-Ketoglutarate), alanyl glutamine (L-Alany-L-Glutamine), beta-alanine (beta-alanine), and pyroglutamate (L-Pyroglutamate) can effectively promote the secretion of endogenous growth hormone and improve the level of endogenous growth hormone. In addition, the composition can be administered orally, effectively solving the problem of poor compliance caused by traditional injection methods, and helping to ensure long-term efficacy.

According to an embodiment of the present invention, the weight ratio of tyrosine to ornithine is (1-2): (1-2); the weight ratio of alanyl glutamine to arginine is (1-2): (1-2). The inventors have experimentally found that there is a synergistic effect between tyrosine and ornithine, and between alanyl glutamine and arginine, which jointly promote the secretion of endogenous growth hormone. Furthermore, the inventors have obtained the above-mentioned preferred ratio through a large number of experiments, thereby better promoting the secretion of endogenous growth hormone.

According to an embodiment of the present invention, the composition includes: 8-12 parts by weight of tyrosine; 8-12 parts by weight of arginine; 8-12 parts by weight of ornithine; 5-7 parts by weight of lysine; 5-7 parts by weight of glutamine; 5-7 parts by weight of glycine; 5-7 parts by weight of isoleucine; 5-7 parts by weight of leucine; 5-7 parts by weight of valine; 5-7 parts by weight of threonine; 5-7 parts by weight of methionine; 5-7 parts by weight of phenylalanine; 5-7 parts by weight of ornithine α-ketoglutarate; 8-12 parts by weight of alanyl-glutamine; 5-7 parts by weight of β-alanine; 5-7 parts by weight of pyroglutamate. The inventor obtained the above-mentioned preferred ratio through a large number of experiments, thereby further promoting the secretion of endogenous growth hormone. In a preferred embodiment, the composition comprises: 10 parts by weight of tyrosine; 10 parts by weight of arginine; 10 parts by weight of ornithine; 6.7 parts by weight of lysine; 6.7 parts by weight of glutamine; 6.7 parts by weight of glycine; 6.7 parts by weight of isoleucine; 6.7 parts by weight of leucine; 6.7 parts by weight of valine; 6.7 parts by weight of threonine; 6.7 parts by weight of methionine; 6.7 parts by weight of phenylalanine; 6.7 parts by weight of ornithine α-ketoglutarate; 10 parts by weight of alanyl-glutamine; 6.7 parts by weight of β-alanine; 6.7 parts by weight of pyroglutamate.

Medicines, health foods, special medical purpose formula foods or feeds

In another aspect of the present invention, the present invention provides a medicine, health food, special medical formula food or feed. According to an embodiment of the present invention, the medicine, health food, special medical formula food or feed includes: the above-mentioned composition. Therefore, the medicine, health food, special medical formula food (also referred to as "special medical food" in the present invention) or feed according to the embodiment of the present invention can effectively promote the secretion of endogenous growth hormone and increase the level of endogenous growth hormone.

According to an embodiment of the present invention, the dosage form of the medicine, health food, special medical purpose formula food or feed is selected from a mixture, tablet, granule, syrup, capsule or oral solution.

It should be noted that the medicine, health food, special medical food or feed of the present invention may further include acceptable adjuvants in medicine, food or feed, specifically, may include excipients, lubricants, preservatives, fillers, solubilizers, stabilizers, etc., for example, lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gel, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, etc. For feed, it may further include conventionally added substances for ensuring normal growth and metabolic needs, such as diet.

The present invention does not strictly limit the intake method of drugs, special medical foods, health foods or , health foods and feeds are limited to intake through the digestive tract, such as oral; special medical foods can be taken orally or by tube feeding, which is convenient for people with limited food intake; the drug can be administered by peritoneal, intravenous, intramuscular, subcutaneous, cortical, oral, nasal, pulmonary and rectal administration, etc. Among them, the oral method is preferred, which is convenient to use and has good compliance, effectively solving the problem of poor compliance caused by traditional injection methods, and helping to ensure long-term efficacy.

use

In another aspect of the present invention, the present invention provides the use of the above-mentioned composition in the preparation of medicines, health foods, special medical formula foods or feeds. According to an embodiment of the present invention, the medicines, health foods, special medical formula foods or feeds are used to promote the secretion of endogenous growth hormone.

According to an embodiment of the present invention, the administration method of the drug, health food, special medical purpose formula food or feed is selected from oral administration. Therefore, it is convenient to administer, has good compliance, and helps to ensure long-term efficacy.

According to an embodiment of the present invention, the drug is used to prevent or treat a disease caused by endogenous growth hormone deficiency. In some embodiments, the disease is selected from dwarfism and/or osteoporosis.

In the present invention, the term "treatment" is used to refer to obtaining the desired pharmacological and/or physiological effect. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and/or may be therapeutic in terms of partially or completely curing a disease and/or adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, especially humans, including: (a) preventing the occurrence of a disease or condition in individuals who are susceptible to the disease but have not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a drug containing the composition described herein to an individual in need.

The administration frequency and dosage of the drug of the present invention can be determined by a number of relevant factors, including the type of disease to be treated, the route of administration, the patient's age, sex, weight and severity of the disease, and the type of drug as the active ingredient. According to some embodiments of the present invention, the daily dose can be divided into 1, 2 or more doses in a suitable form, so that it can be administered once, twice or more times over the entire time period, as long as the therapeutically effective amount is reached.

The term "therapeutically effective amount" refers to an amount of a drug sufficient to significantly improve certain symptoms associated with a disease or condition, that is, an amount that provides a therapeutic effect for a given condition and dosing regimen. For example, in treatment, a drug that reduces, prevents, delays, inhibits or blocks any symptom of a disease or condition should be therapeutically effective. A therapeutically effective amount of a drug does not need to cure a disease or condition, but will provide treatment for the disease or condition so that the onset of the disease or condition in an individual is delayed, stopped or prevented, or the symptoms of the disease or condition are alleviated, or the duration of the disease or condition is changed, or, for example, the disease or condition becomes less severe, or recovery is accelerated.

The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

Example 1

C57BL/6J mice were fed with the following dosages of the experimental group formula, and 2 μl of whole blood was drawn from the tail vein at 20 o'clock on the 15th, 30th, 45th and 60th days after feeding to detect the growth hormone level of the mice. For details on the growth hormone detection method, please refer to the literature "Steyn, F.J., Huang, L., Ngo, S.T., Leong, J.W., Tan, H.Y., Xie, T.Y., Parlow, A.F., Veldhuis, J.D., Waters, M.J., & Chen, C. (2011). Development of a method for the determination of pulsatile growth hormone secretion in mice. Endocrinology, 152(8), 3165–3171. https://doi.org/10.1210/en.2011-0253".

Experimental group 1: 10 mg/kg tyrosine; 10 mg/kg arginine; 10 mg/kg ornithine; 6.7 mg/kg lysine; 6.7 mg/kg glutamine; 6.7 mg/kg glycine; 6.7 mg/kg isoleucine; 6.7 mg/kg leucine; 6.7 mg/kg valine; 6.7 mg/kg threonine; 6.7 mg/kg methionine; 6.7 mg/kg phenylalanine; 6.7 mg/kg ornithine αα-ketoglutarate; 10 mg/kg alanyl-glutamine; 6.7 mg/kg ββ-alanine; 6.7 mg/kg pyroglutamate, based on mouse body weight.

Experimental group 2: 60 mg/kg of tyrosine, based on mouse body weight.

Experimental Group 3: 60 mg/kg of ornithine, based on mouse body weight.

Experimental group 4: 30 mg/kg of tyrosine, 30 mg/kg of ornithine, based on the body weight of mice.

Experimental Group 5: 60 mg/kg alanyl-glutamine, based on mouse body weight.

Experimental Group 6: 60 mg/kg of arginine, based on mouse body weight.

Experimental group 7: 30 mg/kg alanyl-glutamine, 30 mg/kg arginine, based on mouse body weight.

Control group: no addition.

The results are shown in FIG1 . It can be seen that compared with the control group, the whole blood growth hormone level of mice was the highest after being given the composition of the experimental group 1, indicating that the formula can effectively promote the secretion of growth hormone and increase the level of growth hormone.

As shown in Figures 2 and 3, there is a synergistic effect between tyrosine and ornithine, and between alanyl-glutamine and arginine, which jointly promote the secretion of endogenous growth hormone.

Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims (5)

1. A pharmaceutical composition, characterized in that the pharmaceutical composition consists of 10 parts by weight of tyrosine; 10 parts by weight of arginine; 10 parts by weight of ornithine; 6.7 parts by weight of lysine; 6.7 parts by weight of glutamine; 6.7 parts by weight of glycine; 6.7 parts by weight of isoleucine; 6.7 parts by weight of leucine; 6.7 parts by weight of valine; 6.7 parts by weight of threonine; 6.7 parts by weight of methionine; 6.7 parts by weight of phenylalanine; 6.7 parts by weight of ornithine α-ketoglutarate; 10 parts by weight of alanyl-glutamine; 6.7 parts by weight of β-alanine; and 6.7 parts by weight of pyroglutamate. 2. The pharmaceutical composition according to claim 1, characterized in that it comprises: pharmaceutically acceptable excipients. 3. The pharmaceutical composition according to claim 1, characterized in that the dosage form of the pharmaceutical composition is selected from a mixture, tablets, granules, syrup, capsules or oral liquid. 4. Use of the pharmaceutical composition according to claim 1 in the preparation of a drug, characterized in that the drug is used to prevent or treat diseases caused by endogenous growth hormone deficiency; The disease is selected from dwarfism and/or osteoporosis. 5. The use according to claim 4, characterized in that the administration method of the drug is selected from oral administration.